RA Capital Nexus Fund II, L.P. bought $435K of Werewolf Therapeutics (HOWL)
Executed May 12 2025, disclosed May 14 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 14 2025), the stock returned +26.5% (delay-adjusted); from the execution session (May 12 2025), +58.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
RA Capital Nexus Fund II, L.P. (Director) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Werewolf Therapeutics, Inc. (HOWL). Across 1 priced purchase filing, the average 21-session return was +58.7% from execution and +26.5% from disclosure (delay-adjusted; derived). The largest single filing was $435K of HOWL (483,452 sh across 2 lots, as filed), executed May 12 2025.
Healthcare · Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's imm…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→